Broadly neutralizing anti-HIV-1 monoclonal antibodies in the clinic.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 30936546.
- Also identified by DOI 10.1038/s41591-019-0412-8 and PMC identifier 7322694.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Combination anti-retroviral therapy (ART) has revolutionized the treatment and prevention of HIV-1 infection. Taken daily, ART prevents and suppresses the infection. However, ART interruption almost invariably leads to rebound viremia in infected individuals due to a long-lived latent reservoir of integrated proviruses. Therefore, ART must be administered on a life-long basis. Here we review recent preclinical and clinical studies suggesting that immunotherapy may be an alternative or an adjuvant to ART because, in addition to preventing new infections, anti-HIV-1 antibodies clear the virus, directly kill infected cells and produce immune complexes that can enhance host immunity to the virus.
Medical subject headings
- Antibodies, Monoclonal
- Antibodies, Neutralizing
- HIV Antibodies
- HIV Infections
- HIV-1